RESUMEN
Objective To investigate the expression of lncRNA HOTAIR, HOTAIR, CRNDE and AFAP1-AS1 in lung cancer patients with bone metastasis (LCWBM), and to elucidate the diagnostic value of lncRNAs for LCWBM. Methods Serum was collected from 38 LCWBM patients and 38 lung cancer without bone metastasis (LCWOBM) patients. Questionnaires were used to collect basic information of patients. Fasting peripheral venous blood of patients was collected to separate serum. qRT-PCR was used to measure the expression levels of four serum lncRNAs, and their diagnostic value for LCWBM was analyzed. Results The expression of serum HOTAIR was decreased in LCWBM patients, compared with LCWOBM patients (P < 0.05); the AUC of serum HOTAIR diagnosing LCWBM was 0.722 (sensitivity was 70.0%, specificity was 81.3%). And the level of serum HOTTIP was significantly increased in LCWBM patients, compared with LCWOBM patients (P < 0.05); AUC of serum HOTTIP diagnosing LCWBM was 0.784 (sensitivity was 100.0%, specificity was 45.5%). The AUC of serum HOTAIR combined with HOTTIP diagnosing LCWBM was 0.818 (sensitivity, specificity, positive predictive value and negative predictive value were 87.5%, 72.7%, 70.0% and 88.9%, respectively). Conclusion Serum lncRNA HOTAIR and HOTTIP might be potential diagnostic biomarkers for bone metastases in lung cancer patients.
RESUMEN
Objective To explore the efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone metastasis. Methods Four hundred and one cancer patients with bone metas-tasis during 2012 Jan to 2016 Jan in Affiliated Tumor Hospital of Guangxi Medical University were included by a prospective study. According to different therapy ,these patients were randomly divided into three groups:radionu-clide 89SrCl2 group(n=111),Yunke group(n=130)and combined therapy group(n=160). The effect of pain relief and adverse reaction among three groups were compared after therapy. Results Compared with single using radionuclide 89SrCl2 or Yunke ,the cancer pain and bone metastasis in combined-using group were significantly re-lieved with effective rate of 91.25%and 98.75%respectively;the incidence of'pain shine'(11.7%),leucopenia (10.8%)and thrombocytopenia(6.3%)in combined-using group were both lower than single-using group. The ef-fective rate of cancer pain and bone metastasis relief ,and incidence of adverse reaction among single using radionu-clide 89SrCl2 or Yunke were similar. Conclusion Combined-using radionuclide 89SrCl2 and Yunke would effectively and safely relieve cancer with bone metastasis.
RESUMEN
Objective To explore the efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone metastasis. Methods Four hundred and one cancer patients with bone metas-tasis during 2012 Jan to 2016 Jan in Affiliated Tumor Hospital of Guangxi Medical University were included by a prospective study. According to different therapy ,these patients were randomly divided into three groups:radionu-clide 89SrCl2 group(n=111),Yunke group(n=130)and combined therapy group(n=160). The effect of pain relief and adverse reaction among three groups were compared after therapy. Results Compared with single using radionuclide 89SrCl2 or Yunke ,the cancer pain and bone metastasis in combined-using group were significantly re-lieved with effective rate of 91.25%and 98.75%respectively;the incidence of'pain shine'(11.7%),leucopenia (10.8%)and thrombocytopenia(6.3%)in combined-using group were both lower than single-using group. The ef-fective rate of cancer pain and bone metastasis relief ,and incidence of adverse reaction among single using radionu-clide 89SrCl2 or Yunke were similar. Conclusion Combined-using radionuclide 89SrCl2 and Yunke would effectively and safely relieve cancer with bone metastasis.